Regeneron’s Q3 2025 Earnings: What to Expect

Core Insights - Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases, with a market cap of $59.1 billion, and is set to announce its fiscal Q3 earnings for 2025 on October 28 [1] Financial Performance - Analysts expect Regeneron to report a profit of $7.80 per share for Q3 2025, a decrease of 33.5% from $11.73 per share in the same quarter last year [2] - For fiscal 2025, the expected profit is $32.36 per share, down 16.2% from $38.62 per share in fiscal 2024, with a further decline of 2.4% anticipated for fiscal 2026 [3] Stock Performance - Regeneron's stock has declined 44.9% over the past 52 weeks, underperforming compared to the S&P 500 Index's 12.3% return and the Health Care Select Sector SPDR Fund's 8.6% drop [4] - Following a better-than-expected Q2 earnings release, Regeneron's shares surged 2.5%, with overall revenue improving 3.6% year-over-year to $3.7 billion, exceeding analyst expectations by 10.2% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for Regeneron, with 18 out of 27 analysts recommending "Strong Buy," and a mean price target of $729.85, indicating a potential upside of 29.5% from current levels [6]